ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Effects of Exercise and Sertraline on Measures of Coronary Heart Disease Risk in Patients With Major Depression: Results From the SMILE-II Randomized Clinical Trial

Sherwood Andrew*; Blumenthal James A; Smith Patrick J; Watkins Lana L; Hoffman Benson M; Hinderliter Alan L
PSYCHOSOMATIC MEDICINE2016-6DOI: 10.1097/PSY.0000000000000301
3阅读
引用收藏
分享

摘要

Objective To assess the effects of supervised and home-based aerobic exercise training, and antidepressant pharmacotherapy (sertraline) on coronary heart disease (CHD) risk factors in a sample of participants with major depressive disorder (MDD). <br>Methods The Standard Medical Intervention versus Long-term Exercise (SMILE)-II study randomized 202 adults (153 women, 49 men) diagnosed as having MDD to one of four interventions, each of 4-month duration: supervised exercise, home-based exercise, antidepressant medication (sertraline, 50-200 mg daily), or placebo pill. Patients underwent a structured clinical interview for depression and completed the Hamilton Depression Rating Scale. CHD risk factors included brachial artery flow-mediated dilation, carotid intima-media thickness, serum lipids, and 10-year atherosclerotic cardiovascular disease (ASCVD) risk. <br>Results Compared with placebo, active treatment of depression (supervised exercise, home-based exercise, sertraline therapy) was associated with an improvement in CHD risk factors (improved flow-mediated dilation [p = .032], reduced progression of intima-media thickness [p = .037], and a reduction in 10-year ASCVD [p = .049]). The active treatments did not differ from each other in their effects on the CHD risk outcomes. <br>Conclusions Both exercise and antidepressant medication improved CHD risk factors and lowered ASCVD risk in patients with MDD. Because MDD is associated with increased risk for CHD events, treatment of depression with exercise or sertraline may reduce the risk of developing CHD in patients with MDD. Trial Registration: Clinical Trials Government Identifier: NCT-00331305.

学科与关键词

关键词
depressionexerciseantidepressant medicationatherosclerosiscarotid intima-media thicknessflow-mediated dilation
相关
加载中…
  • Direction of Association Between Depressive Symptoms and Lifestyle Behaviors in Patients with Coronary Heart Disease: the Heart and Soul Study
    Sin Nancy L*; Kumar Anupama D; Gehi Anil K; Whooley Mary AANNALS OF BEHAVIORAL MEDICINE, 2016, 50(4): 523-532.
  • Escitalopram does not improve outcomes for depressed patients with heart failure
    Clinical Pharmacist, 2016.
  • Optimism, Response to Treatment of Depression, and Rehospitalization After Coronary Artery Bypass Graft Surgery
    Hilary Tindle; Bea Herbeck Belnap; Patricia R. Houck; Sati Mazumdar; Michael F. Scheier; Karen A. Matthews; Fanyin He; Bruce L. RollmanPsychosomatic Medicine, 2012, 74(2): 200-207.
查看全部 →

发表信息

论文状态
公开发表
期刊
PSYCHOSOMATIC MEDICINE
发表日期
2016-06
卷期
第 78 卷, 第 5 期
页码
602-609
DOI
10.1097/PSY.0000000000000301
语言
ENGLISH
成果收录
SSCI
资助标注
National Institutes of Health [MH49679, HL093374, HL101383]; National Institutes of Health from the National Center for Research Resources, Clinical Research Centers Program [MO1-RR-30]; Pfizer Pharmaceuticals, Inc.

作者

  • S

    Sherwood Andrew (通讯) (第一作者)

  • B

    Blumenthal James A

查看全部 6 位作者收起作者
  • S

    Smith Patrick J

  • W

    Watkins Lana L

  • H

    Hoffman Benson M

  • H

    Hinderliter Alan L

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417